KIN-102
Solid Tumors
IND-enablingActive
Key Facts
About Kinimmune
Kinimmune is a private, clinical-stage biotech founded in 2020 and based in Cambridge, USA, targeting the significant unmet need in solid tumor immunotherapy. The company's core approach involves formulating intratumoral immunostimulants with improved tissue retention to safely 'step on the gas' of the immune system, thereby unlocking the full potential of checkpoint blockade. With a pipeline featuring both 505(b)(2) and new chemical entity (NCE) programs, Kinimmune aims to broaden the therapeutic window and improve patient outcomes. The company is currently pre-revenue, advancing its lead asset, KIN-101, into clinical development.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK4362676 | GSK plc | Phase 1 |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| ABBV-154 | AbbVie | Phase 1 |
| TAK-981 | Takeda Pharmaceutical | Phase 1/2 |
| TAK-676 | Takeda Pharmaceutical | Phase 1 |
| TAK-573 | Takeda Pharmaceutical | Phase 1 |
| TAK-164 | Takeda Pharmaceutical | Phase 1 |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase 1/2 |
| BAY 2927088 | Bayer | Phase 1 |
| ASP1929 | Astellas Pharma | Phase 2 |
| IBI188 | Innovent Biologics | Phase 1 |
| Bispecific Antibody | Akeso | Phase 1/2 |